1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Medico Remedies Limited

Medico Remedies Limited

MEDICO.BO
Medico Remedies LimitedIN flagBombay Stock Exchange
40.39
INR
-0.61
- -
3.37BMarket Cap
Medico Remedies Limited
MEDICO.BO
(Bombay Stock Exchange)

Recent

price

40.39

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
4.07
5.41
6.14
8.04
6.56
9.12
11.77
10.68
14.44
14.26
16.69
17.27
18.24
- -
25.01
Revenue per Share
0.05
0.08
0.1
0.14
0.2
0.18
0.19
0.2
0.31
0.58
0.87
1
1.22
- -
1.59
Basic EPS, GAAP
0.03
-0.18
-0.29
-0.49
-0.49
0.64
0.15
-0.28
-3.41
-0.01
0.19
- -
0.21
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.12
0.15
0.19
0.19
1.05
1.62
1.5
1.69
1.93
4.01
4.88
5.88
7.12
- -
2.01
Book Value per Share
0.61
1.03
1.64
1.78
1.97
3.98
3.4
3.6
3.83
4.41
5.27
6.3
7.54
- -
9.14
Tangible Book Value per Share
83
83
83
83
83
67
83
83
83
83
83
83
83
- -
83
Basic Weighted Avg Shares
337
449
510
667
544
610
977
886
1,198
1,183
1,385
1,433
1,509
2,064
2,064
Sales/Revenue/Turnover
3.11
3.24
3.24
3.93
5.72
4.06
1.28
1.33
4.64
4.49
4.98
7
7.93
6.75
6.75
Operating Margin (%)
4
7
13
12
11
10
15
17
16
44
54
29
30
31
31
Depreciation Expense
4
6
8
11
16
12
16
16
26
48
72
83
101
131
131
Net Income, GAAP
39.4
34.33
28.08
39.62
3.56
34.84
27.81
26.4
30
25.78
28.29
26.86
25.26
27.38
27.38
Effective Tax Rate (%)
1.27
1.4
1.55
1.69
2.99
2
1.61
1.84
2.16
4.07
5.23
5.79
6.69
6.35
6.36
Profit Margin (%)
10
14
47
104
170
155
137
162
198
194
228
309
397
513
513
Working Capital
- -
- -
- -
37
108
22
24
47
50
26
13
9
4
3
3
LT Debt
51
86
136
147
164
267
282
299
318
366
438
524
625
755
755
Total Equity
- -
6.91
6.17
6.32
9.32
4.3
2.23
2.03
8.64
8.29
9.65
12.81
12.83
11.49
11.49
Return on Invested Capital (%)
- -
12.67
14.46
13.18
12.33
7.76
8.3
8.33
10.65
13.49
15.93
16.36
16.8
26.38
26.38
Return on Capital (%)
- -
54.95
55.38
70.62
31.65
12.49
13.49
12.31
17.23
19.53
19.63
18.57
18.74
34.75
34.75
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
124
- -
189
LT Borrowings
- -
- -
3
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
83
- -
83
Market Capitalization
3,928
4,184
2,693

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
1,138
- -
1,289
Cash, Cash Equivalents & STI
18
- -
38
Accounts Receivable, Net
574
- -
820
Inventories
414
- -
300
Total Current Liabilities
704
- -
776
Payables & Accruals
- -
- -
- -
ST Debt
124
- -
189
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.65%
18.87%
20.82%
Free Cash Flow
-722.78%
-1,551.92%
-18.79%
Net Income, GAAP
31.29%
40.49%
29.94%
Sales/Revenue/Turnover
14.11%
12.26%
36.73%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
315
424
298
397
1,433
2025
308
393
395
413
1,509
2026
383
526
587
568
2,064

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.29
0.17
- -
1
2025
0.19
0.19
0.32
0.52
1.22
2026
0.22
0.31
0.35
0.71
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Juva Life Inc. (JUVAF)
Alvotech (ALVOW)
Vifor Pharma AG (GNHAY)
Almirall, S.A. (ALM.MC)
Changchun High-Tech Industries (Group) Inc. (000661.SZ)
Piramal Enterprises Limited (PEL.NS)
Business
Medico Remedies Limited (MEDICO.BO), a pharmaceutical formulation manufacturing and marketing company, develops, manufactures and sells a broad range of generic pharmaceutical and nutraceutical products including antibiotics and anti-infectives; beta-lactams such as penicillins and cephalosporins; antifungals; vitamins, haematinics and nutritional supplements; cardiovascular drugs; antipyretic, analgesic and NSAID medicines; antacids and anti-ulcer drugs; antidepressants, antipsychotics and anti-epileptics; antimalarials and antiretrovirals; dry syrups; ointments and creams; anti-diabetics; liquid syrups; diuretics; steroidal preparations; and miscellaneous combination drug kits for various therapeutic segments. The company, founded in 1994 and headquartered in Mumbai, India, with manufacturing facilities in Palghar, Maharashtra, operates seven WHO-GMP-certified production units and serves domestic markets alongside exports to countries including Bangladesh, Nepal, Yemen, Saudi Arabia and Mozambique. In March 2025, Medico Remedies expanded into ointment production with new state-of-the-art facilities approved under international standards such as WHO GMP, ISO 9001:2015 and approvals from US FDA and European regulators, diversifying its topical offerings to bolster global presence and growth; in April 2025, it secured a government supply order worth approximately Rs 16 crore (USD 1.9 million) from the Dominican Republic's PROMESE/CAL program for tablets, capsules and dry syrups, underscoring its strengthening international footprint in regulated markets.